tirzepatide nda appears to be more effective than standard care in early type 2 diabetes NAD+ and Tirzepatide: The Metabolism

GLP-1 receptor agonists are incretin-based therapies that: Enhance glucose-dependent insulin secretion Suppress glucagon release Slow gastric emptying Promote satiety and weight loss Common medications include: Semaglutide Tirzepatide Dulaglutide Liraglutide Their ability to delay gastric emptying is central to both their therapeutic benefits and perioperative risks

Can J Chem Eng

Semaglutide and Tirzepatide were originally developed to treat type II diabetes by controlling blood sugar levels but have since been found to assist in weight loss management

Aug 2014;17(4):325-35

10.3390/molecules26237109 Molecules

"Many reported oral effects appear to be secondary to the gastrointestinal side effects of GLP-1 therapy rather than direct oral toxicity," says Chole Tsang, DMD, a dentist at Tend in New York City